| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Scinai Immunotherapeutics Ltd.
13G/A
Amendment 7
09073Q203
|
9.9% |
7/1/2026
Event 6/4/2026
|
|||
| Stone Daniel E. | 9.9% | ||||
| RK Stone Miami, LLC | 7.1% | ||||
|
Scinai Immunotherapeutics Ltd.
13G/A
Amendment 6
09073Q203
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Stone Daniel E. | 9.9% | ||||
| RK Stone Miami, LLC | 6.7% | ||||
|
Scinai Immunotherapeutics Ltd.
13G/A
Amendment 5
09073Q203
|
9.9% |
10/1/2025
Event 9/29/2025
|
|||
| Stone Daniel E. | 9.9% | ||||
| RK Stone Miami, LLC | 8.1% | ||||
|
Scinai Immunotherapeutics Ltd.
13G/A
Amendment 4
09073Q203
|
10.0% |
1/24/2025
Event 12/31/2024
|
|||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.